Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
Clinical trial NCT03947216 · COMPLETED
Trial details
- NCT number
- NCT03947216
- Sponsor
- University Hospital, Strasbourg, France
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-23
- Primary completion
- 2024-04-23
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.